Geode Capital Management
CRSP icon

Geode Capital Management’s CRISPR Therapeutics CRSP Stock Holding History

Geode Capital Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$113M Buy
2,377,164
+127,941
+6% +$6.75M 0.01% 1005
2025
Q4 		$118M Buy
2,249,223
+108,053
+5% +$6.47M 0.01% 969
2025
Q3 		$139M Buy
2,141,170
+69,287
+3% +$3.98M 0.01% 877
2025
Q2 		$101M Buy
2,071,883
+1,025,979
+98% +$39.7M 0.01% 1020
2025
Q1 		$35.6M Buy
1,045,904
+45,036
+4% +$1.91M ﹤0.01% 1573
2024
Q4 		$39.4M Sell
1,000,868
-7,346
-0.7% -$347K ﹤0.01% 1581
2024
Q3 		$47.4M Buy
1,008,214
+35,196
+4% +$1.79M ﹤0.01% 1457
2024
Q2 		$52.6M Buy
973,018
+63,720
+7% +$3.69M ﹤0.01% 1329
2024
Q1 		$62M Buy
909,298
+25,569
+3% +$1.83M 0.01% 1206
2023
Q4 		$55.3M Buy
883,729
+33,791
+4% +$1.87M 0.01% 1280
2023
Q3 		$38.6M Buy
849,938
+15,331
+2% +$792K ﹤0.01% 1401
2023
Q2 		$46.9M Buy
834,607
+24,623
+3% +$1.4M 0.01% 1295
2023
Q1 		$36.6M Buy
809,984
+20,886
+3% +$1.01M ﹤0.01% 1402
2022
Q4 		$32.1M Buy
789,098
+24,422
+3% +$1.3M ﹤0.01% 1454
2022
Q3 		$50M Buy
764,676
+50,481
+7% +$3.66M 0.01% 1091
2022
Q2 		$43.4M Buy
714,195
+51,106
+8% +$3M 0.01% 1223
2022
Q1 		$41.6M Buy
663,089
+596,823
+901% +$37.5M 0.01% 1382
2021
Q4 		$5.02M Buy
66,266
+1,811
+3% +$158K ﹤0.01% 2900
2021
Q3 		$7.21M Buy
64,455
+600
+0.9% +$75.4K ﹤0.01% 2696
2021
Q2 		$10.3M Sell
63,855
-181
-0.3% -$22K ﹤0.01% 2431
2021
Q1 		$7.8M Buy
64,036
+11,536
+22% +$1.74M ﹤0.01% 2525
2020
Q4 		$8.04M Buy
52,500
+1,262
+2% +$149K ﹤0.01% 2307
2020
Q3 		$4.29M Buy
51,238
+3,839
+8% +$341K ﹤0.01% 2484
2020
Q2 		$3.48M Buy
47,399
+4,449
+10% +$260K ﹤0.01% 2528
2020
Q1 		$1.82M Buy
42,950
+3,716
+9% +$192K ﹤0.01% 2718
2019
Q4 		$2.39M Buy
39,234
+758
+2% +$41.4K ﹤0.01% 2905
2019
Q3 		$1.58M Sell
38,476
-224
-0.6% -$10.7K ﹤0.01% 3059
2019
Q2 		$1.82M Buy
38,700
+112
+0.3% +$4.48K ﹤0.01% 3011
2019
Q1 		$1.38M Buy
38,588
+3,615
+10% +$125K ﹤0.01% 3030
2018
Q4 		$999K Sell
34,973
-852
-2% -$29.6K ﹤0.01% 3114
2018
Q3 		$1.59M Buy
35,825
+330
+0.9% +$17.3K ﹤0.01% 3008
2018
Q2 		$2.08M Buy
35,495
+7,982
+29% +$455K ﹤0.01% 2834
2018
Q1 		$1.26M Buy
27,513
+525
+2% +$21.7K ﹤0.01% 3011
2017
Q4 		$633K Buy
26,988
+570
+2% +$10.8K ﹤0.01% 3274
2017
Q3 		$472K Buy
26,418
+8,032
+44% +$146K ﹤0.01% 3387
2017
Q2 		$294K Sell
18,386
-2,724
-13% -$45K ﹤0.01% 3546
2017
Q1 		$459K Buy
21,110
+2,760
+15% +$54.2K ﹤0.01% 3336
2016
Q4 		$371K Buy
+18,350
New +$343K ﹤0.01% 3384

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Geode Capital Management's CRSP Position: Q1 2026 in Review

Geode Capital Management increased its CRISPR Therapeutics (CRSP) stake by 5.7% in Q1 2026, buying an estimated $6.75M and bringing the position to 2,377,164 shares worth $113M. The position accounts for 0.01% of the portfolio, ranked #1005.

Geode Capital Management first reported a position in CRSP in Q4 2016 and has held it in 38 quarters since. The position peaked at $139M in Q3 2025. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Geode Capital Management held 2,377,164 shares of CRISPR Therapeutics worth $113M as of Q1 2026.
  • Geode Capital Management bought 127,941 CRISPR Therapeutics shares in Q1 2026, an estimated $6.75M.
  • CRISPR Therapeutics made up 0.01% of Geode Capital Management's portfolio in Q1 2026, its #1005 holding.
  • Geode Capital Management first reported a position in CRISPR Therapeutics in Q4 2016 and has held it in 38 quarters since.
  • Geode Capital Management's CRISPR Therapeutics position peaked at $139M in Q3 2025.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.